BioSpace News Archive

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, reported financial results for the third quarter ended September 30, 2019 and provided a general business update.

Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced financial results for the third quarter ended September 30, 2019.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that its management team will be presenting at the Stifel 2019 Healthcare Conference on November 19, 2019 at the Lotte New York Palace Hotel in New York.

Geron Corporation reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events.

ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, reported financial results for the quarter ended September 30, 2019 and provided a corporate update.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the third quarter 2019 and provided an operational update.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the third quarter ended September 30, 2019.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, announced its results for the third quarter and provided an update on the company’s recent activities.

Quotient Limited, a commercial-stage diagnostics company, announced the Company intends to commence an underwritten public offering of its ordinary shares.

Transformation delivers significant improvement in profitability and free cash flow Full year 2019 and 2020 guidance reaffirmed Reduced convertible debt due in 2021 by $16 million